<DOC>
	<DOCNO>NCT00767728</DOCNO>
	<brief_summary>The purpose study compare maintenance mild moderate ulcerative colitis remission six month treatment 1.5 gram mesalamine pellet day versus placebo .</brief_summary>
	<brief_title>Mesalamine Pellet Maintain Remission Mild Moderate Ulcerative Colitis</brief_title>
	<detailed_description>This Phase 3 study evaluate effectiveness safety eMG 1.5 g give daily ( QD ) compare placebo subject demonstrate remission UC . Eligible subject randomize 2:1 ratio ( active : placebo ) receive 1 2 treatment : 1.5g eMG ( 4 capsule total ) match placebo capsule QD 6 month . The study consist screen phase ( complete within 7 day prior randomization ) , treatment phase ( 6 month ) , follow-up visit ( 2 week end-of-study [ EOS ] visit . ) The treatment phase consist 4 schedule study visit : visit 1 ( baseline/randomization ( day 1 ) , visit 2 ( month 1 ) , visit 3 ( month 3 ) , visit 4 ( EOS ( month 6 ) . Primary objective : To compare maintenance remission mild moderate ulcerative colitis measure rectal bleeding endoscopic mucosal appearance 6 month treatment encapsulate mesalamine granule ( eMG ) 1.5 g QD , compare placebo . Secondary objective : To compare safety tolerability long-term dosing eMG 1.5 g QD compare placebo maintenance remission mild moderate UC .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Confirmed diagnosis ulcerative colitis remission least 1 month Greater 18 year age Allergy/intolerance aspirin , mesalamine , salicylates Prior bowel surgery appendectomy Pregnancy , risk pregnancy , lactate HIV hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>UC</keyword>
	<keyword>ulcerative colitis</keyword>
	<keyword>IBD</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>